News | July 28, 2022
Biocon Q1FY23 consolidated PAT falls QoQ at Rs. 144.4 Cr
Biocon has reported total income of Rs. 2217.4 crores during the period ended June 30, 2022.
Biocon has reported total income of Rs. 2217.4 crores during the period ended June 30, 2022.
Sanjay Verma of Akums Drugs & Pharmaceuticals, Manu Gupta of Cadila Pharmaceuticals, Rahul Borse of RPG Life Sciences, Krishna Sai T of Biocon and Amit Saluja of NASSCOM are speakers
This further adds to Biocon’s portfolio of vertically integrated complex drug products
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
The company has received a certificate of Good Manufacturing Practice compliance from the Medicines & Healthcare products Regulatory Agency (MHRA) UK
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.
Subscribe To Our Newsletter & Stay Updated
